Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy

被引：10

作者：

Boglione, L. ^{[1
]}

De Nicolo, A. ^{[1
]}

Cardellino, C. S. ^{[1
]}

Ruggiero, T. ^{[1
]}

Ghisetti, V. ^{[1
]}

Cariti, G. ^{[1
]}

Di Perri, G. ^{[1
]}

D'Avolio, A. ^{[1
]}

机构：

[1] Univ Turin, Amedeo di Savoia Hosp, Dept Infect Dis, Cso Svizzera 164, Turin, Italy

来源：

CLINICAL MICROBIOLOGY AND INFECTION | 2015年 / 21卷 / 02期

关键词：

Boceprevir; breakthrough; HCV; resistance; triple therapy; CHRONIC HEPATITIS-C; PROTEASE INHIBITOR; RESISTANCE MUTATIONS; NAIVE PATIENTS; TELAPREVIR; RIBAVIRIN;

D O I：

10.1016/j.cmi.2014.07.009

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

In a prospective cohort of 18 patients treated with boceprevir, we examined the role of boceprevir plasma concentration at the onset of breakthrough during the treatment. Nine patients experienced breakthrough during therapy. The resistance patterns were as follows: S122S/R, I132V, T54A/I132V, V156S/I170A, V36M/T54S/R155K, V36M/R155K and T54/R155K. Boceprevir-S isomer (SCH 534128) median concentration in patients with breakthrough was 48.3 ng/mL (interquartile range 43-58 ng/mL); in others, it was significantly (p 0.019) higher: 151 ng/mL. Low boceprevir plasma concentration can lead to virologic resistance; therapeutic drug monitoring should be used to prevent the onset of viral breakthrough during triple-regimen therapy with boceprevir. Clinical Microbiology and Infection (C) 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

引用

页码：205.e1 / 205.e3

页数：3

共 16 条

[1] Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies [J].

Barnard, Richard J. O. ;

Howe, John A. ;

Ogert, Robert A. ;

Zeuzem, Stefan ;

Poordad, Fred ;

Gordon, Stuart C. ;

Ralston, Robert ;

Tong, Xiao ;

Sniukiene, Vilma ;

Strizki, Julie ;

Ryan, Desmond ;

Long, Jianmin ;

Qiu, Ping ;

Brass, Clifford A. ;

Albrecht, Janice ;

Burroughs, Margaret ;

Vuocolo, Scott ;

Hazuda, Daria J. .

VIROLOGY, 2013, 444 (1-2) :329-336

[2]

Chen KX, 2010, PROGR MED CHEM, V49, P1, DOI 10.1016/S0079-6468(10)49001-3

[3] Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients [J].

D'Avolio, A ;

Ibañez, A ;

Sciandra, M ;

Siccardi, M ;

de Requena, DG ;

Bonora, S ;

Di Perri, G .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2006, 835 (1-2) :127-130

[4] A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir [J].

D'Avolio, Antonio ;

De Nicolo, Amedeo ;

Agnesod, Danilo ;

Simiele, Marco ;

Abdi, Adnan Mohamed ;

Penchala, Sujan Dilly ;

Boglione, Lucio ;

Cariti, Giuseppe ;

Di Perri, Giovanni .

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2013, 78-79 :217-223

[5] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].

Fried, MW ;

Shiffman, ML ;

Reddy, KR ;

Smith, C ;

Marinos, G ;

Goncales, FL ;

Haussinger, D ;

Diago, M ;

Carosi, G ;

Dhumeaux, D ;

Craxi, A ;

Lin, A ;

Hoffman, J ;

Yu, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982

[6] SAFETY OF TELAPREVIR OR BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA/RIBAVIRIN, IN CIRRHOTIC NON RESPONDERS. FIRST RESULTS OF THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC) [J].

Hezode, C. ;

Dorival, C. ;

Zoulim, F. ;

Poynard, T. ;

Mathurin, P. ;

Pol, S. ;

Larrey, D. ;

Cacoub, P. ;

de Ledinghen, V. ;

Bourliere, M. ;

Bernard, P. H. ;

Riachi, G. ;

Alric, L. ;

Samuel, D. ;

Barthe, Y. ;

Fontaine, H. ;

Carrat, F. ;

Bronowicki, J. -P. .

JOURNAL OF HEPATOLOGY, 2012, 56 :S4-S4

[7] Hepatitis C Viral Evolution in Genotype 1 Treatment-Naive and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials [J].

Kieffer, Tara L. ;

De Meyer, Sandra ;

Bartels, Doug J. ;

Sullivan, James C. ;

Zhang, Eileen Z. ;

Tigges, Ann ;

Dierynck, Inge ;

Spanks, Joan ;

Dorrian, Jennifer ;

Jiang, Min ;

Adiwijaya, Bambang ;

Ghys, Anne ;

Beumont, Maria ;

Kauffman, Robert S. ;

Adda, Nathalie ;

Jacobson, Ira M. ;

Sherman, Kenneth E. ;

Zeuzem, Stefan ;

Kwong, Ann D. ;

Picchio, Gaston .

PLOS ONE, 2012, 7 (04)

[8] Naturally Occurring Dominant Resistance Mutations to Hepatitis C Virus Protease and Polymerase Inhibitors in Treatment-Naive Patients [J].

Kuntzen, Thomas ;

Timm, Joerg ;

Berical, Andrew ;

Lennon, Niall ;

Berlin, Aaron M. ;

Young, Sarah K. ;

Lee, Bongshin ;

Heckerman, David ;

Carlson, Jonathan ;

Reyor, Laura L. ;

Kleyman, Marianna ;

McMahon, Cory M. ;

Birch, Christopher ;

Wiesch, Julian Schulze zur ;

Ledlie, Timothy ;

Koehrsen, Michael ;

Kodira, Chinnappa ;

Roberts, Andrew D. ;

Lauer, Georg M. ;

Rosen, Hugo R. ;

Bihl, Florian ;

Cerny, Andreas ;

Spengler, Ulrich ;

Liu, Zhimin ;

Kim, Arthr Y. ;

Xing, Yanming ;

Schneidewind, Arne ;

Madey, Margaret A. ;

Fleckenstein, Jaquelyn F. ;

Park, Vicki M. ;

Galagan, James E. ;

Nusbaum, Chad ;

Walker, Bruce D. ;

Lake-Bakaar, Gerond V. ;

Daar, Eric S. ;

Jacobson, Ira M. ;

Gomperts, Edivard D. ;

Edlin, Brian R. ;

Donfield, Sharyne M. ;

Chung, Raymond T. ;

Talal, Andrew H. ;

Marion, Tony ;

Birren, Bruce W. ;

Henn, Mattliew R. ;

Allen, Todd M. .

HEPATOLOGY, 2008, 48 (06) :1769-1778

[9]

MOHD HK, 2013, HEPATOLOGY, V57, P1333, DOI DOI 10.1002/HEP.26141

[10] The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naive patients [J].

Nelson, David R. .

LIVER INTERNATIONAL, 2011, 31 :53-57

← 1 2 →